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Abstract
Purpose To assess current antithrombotic treatment strategies
in the Netherlands in patients undergoing transcatheter aortic
valve implantation (TAVI).
Methods For every Dutch hospital performing TAVI (n =14)
an interventional cardiologist experienced in performing TAVI
was interviewed concerning heparin, aspirin, thienopyridine
and oral anticoagulation treatment in patients undergoing
TAVI.
Results The response rate was 100 %. In every centre, a
protocol for antithrombotic treatment after TAVI was avail-
able. Aspirin was prescribed in all centres, concomitant
clopidogrel was prescribed 13 of the 14 centres. Duration
of concomitant clopidogrel was 3 months in over two-
thirds of cases. In 2 centres, duration of concomitant
clopidogrel was based upon type of prosthesis: 6 months
versus 3 months for supra-annular and intra-annular prosthe-
ses, respectively.
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Conclusions Leaning on a small basis of evidence and rec-
ommendations, the antithrombotic policy for patients under-
going TAVI is highly variable in the Netherlands. As a
standardised regimen might further reduce haemorrhagic
complications, large randomised clinical trials may help to
establish the most appropriate approach.
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Introduction
Since its introduction in 2002, TAVI has conquered a substan-
tial portion of aortic interventions. It has become standard
therapy in inoperable patients [1]. Moreover, in high-risk but
operable patients, TAVI has shown to be non-inferior to sur-
gical aortic valve replacement [2]. Due to growing experience,
smaller catheters, and new-generation devices, the rate of
complications has been reduced. However, the incidence of
bleeding and vascular complications remains substantial and
has been proven to affect survival [3, 4].
A standardised antithrombotic treatment may reduce the
rate of these negative outcomes. However, no large
randomised controlled trials have been performed, and current
guidelines report only recommendations [5–7]. The rationale
for this survey was to provide insight into the current anti-
thrombotic policy after TAVI. Results could be of value in
decision-making on treatment policy for both experienced and
inexperienced centres, and provide a basis for further research.
Methods
Setting and data collection
Currently, 14 hospitals in the Netherlands perform TAVI [8].
All centres were approached in the period from February to
April 2013. In each hospital, we contacted the interventional
cardiologist responsible for TAVI by an introduction e-mail
addressing our intention to undertake a national survey. To
maximise compliance, the interview was performed by visit
(n =4) or telephone (n =9). In 1 case, communication was per
e-mail. The interview was structured according to the printed
survey depicted in the “Supplements”.
Assumptions
In the development of the survey, we assumed antithrombotic
treatment could be different per prosthesis or approach. We
suspected it to be more dependent on the approach because of
the bleeding risk, and designed the survey accordingly.
Besides closed questions for plain parameters such as dose
and duration, we added two open questions for which we
expected diverse answers.
Data analysis
Results are categorical and given as frequencies.
Results
Protocol
A local protocol for antithrombotic treatment in patients un-
dergoing TAVI was available in all centres. In the majority of
cases, the protocol was based upon local experience. Regard-
ing the duration of dual antiplatelet therapy (DAPT), centres
often followed the recommendations of the respective com-
panies producing prostheses. These include 3 months of
DAPT for Edwards SAPIENTM (Edwards Lifesciences, Ir-
vine, USA) and 6 months for Medtronic CoreValveTM
(Medtronic, Minneapolis, USA).
Procedure
During the TAVI procedure, all centres used unfractionated
heparin (UFH) as anticoagulant. The dose of UFH was accord-
ing to weight in 3 centres and a standard initial bolus was given
in 11 of the 14 centres, mostly 5000 IU (n =6). Activated
clotting time (ACT) was measured in 13 of the 14 centres.
Target ACTwas >250 s (n =9), >200 s (n=2), or >300 s (n=3).
In patients with an indication for oral anticoagulation
(OAC), 3 centres continued OAC periprocedure with an inter-
national normalised ratio (INR) aimed at 2.0 or <2.5, whereas
11 of the 14 centres discontinued OAC periprocedure. Of these
centres, 1 never performed bridging therapy, 3 always per-
formed bridging therapy, and 7 performed bridging therapy in
patients at high thrombotic risk only (e.g. mechanic mitral
valve) as illustrated in Fig. 1.
Concomitant antiplatelet therapy
In patients without an indication for OAC, all centres pre-
scribed lifelong low-dose aspirin (80–100 mg). When a pa-
tient was not preloaded with aspirin, a loading dose (200–
600 mg) was given in the week prior to procedure, mostly at
day −1 (n =8). In addition to aspirin, 13 centres routinely
prescribed clopidogrel as adjunctive antithrombotic medica-
tion. Clopidogrel was loaded in all centres with a loading dose
of either 300 (n =9) or 600 mg (n =4). All centres prescribed a
maintenance dose of 75 mg for a varying duration of 1 (n =1),
3 (n =9), and 6 (n =3) months (Fig. 2).
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One centre, which only performed transapical procedures,
used no additional clopidogrel at all. In total, 4 centres dis-
criminated in the addition of clopidogrel. In 2 centres, dis-
crimination was based upon prosthesis type: SAPIENTM ver-
sus CoreValveTM. Whereas 1 centre reduced the loading dose
(600 to 300 mg) and the duration (6 to 3 months) after
SAPIENTM implantation, the other centre omitted clopidogrel
completely after SAPIENTM implantation. In the other 2 cen-
tres, discrimination in DAPT was based upon approach:
clopidogrel was loaded at day 0 for transfemoral TAVI and
at day +1 for transapical TAVI.
In patients with an indication for OAC, concomitant anti-
platelet therapy was used in 13 of the 14 centres for all pros-
theses and approaches. Concomitant antiplatelet therapy either
consisted of clopidogrel (n =9) or aspirin (n =4) (Fig. 3). A
single dose of aspirin in addition to clopidogrel at the time of
loading was given in 1 centre. Two centres only used aspirin in
addition to OAC when a patient was already loaded, otherwise
clopidogrel was administered. Clopidogrel was loaded in all
centres with a loading dose of either 300 (n =5) or 600 mg
(n =4). All centres prescribed a maintenance dose of 75 mg for
a varying duration of 1 (n =1), 3 (n =6), and 6 (n =2) months.
Considering aspirin, patients received a loading dose at day −1
(n =1) or day 0 (n =1) and a maintenance dose for 6 months
(n =1) or lifelong (n =3).
In total, 2 of the 14 centres discriminated in the addition of
clopidogrel. In both of these centres, this discrimination was
based upon prosthesis type: SAPIENTM versus CoreValveTM.
Whereas 1 centre reduced the loading dose (600 to 300 mg)
and the duration (6 to 3 months) after SAPIENTM implanta-
tion, the other centre omitted clopidogrel completely after
SAPIENTM implantation. Centres prescribing aspirin did not
discriminate between prosthesis types or approaches.
Bleeding risk
The prescribed antithrombotic regimen was based upon bleed-
ing risk in 7 of the 14 centres. Three centres omitted
clopidogrel completely in case of very high bleeding risk or
severe thrombocytopenia according to local protocol. One
centre reduced the duration of clopidogrel treatment (6 to
3months) in case of a high bleeding risk. Two centres adjusted
the time of commencing and ceasing clopidogrel treatment
individually.
DAPT pre-TAVI
When a patient had undergone a recent (≤1 year) PCI and had
an absolute indication for DAPT prior to TAVI, all centres
continued DAPT. When a patient received a newer
thienopyridine (e.g. prasugrel, ticlopidine), the same therapy
was continued in 8 centres whereas the thienopyridine was
changed to clopidogrel in 2 of the 14 centres. The other 4
centres had no experience with such a scenario.
Fig. 1 Periprocedure antithrombotic policy in patients with an indication
for oral anticoagulation (OAC)
Fig. 2 Duration of dual antiplatelet therapy (DAPT) after TAVI in
patients without an indication for oral anticoagulation (OAC)
Fig. 3 Concomitant antiplatelet therapy after TAVI in patients with an
indication for oral anticoagulation (OAC)
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Triple therapy pre-TAVI
If a patient was receiving triple therapy (i.e. OAC and DAPT)
prior to TAVI, only 1 centre continued this. Triple therapy was
routinely discontinued in 6 centres or continued for as short as
possible (1–2 weeks) in 2 of the 14 centres. Two centres
preferred not to continue triple therapy and adjusted medica-
tion on an individual basis, whereas 3 centres had no experi-
ence with such cases.
If triple therapy was discontinued, aspirin was omitted rou-
tinely in 4 centres and clopidogrel in 1 centre. Two centres
omitted aspirin only when the patient received triple therapy
because of a recent stent and omitted clopidogrel in other cases.
OACwas omitted until clopidogrel could be stopped in 1 centre.
New-onset persistent atrial fibrillation
When a patient developed persistent atrial fibrillation (AF)
after TAVI during the hospitalisation period and had an indi-
cation for OAC, aspirin was replaced by OAC in 9 of the 14
centres. Four centres only replaced aspirin by OAC when the
patient received DAPT prior to TAVI because of a recent stent
and replaced clopidogrel by OAC in other cases. OAC was
added to DAPT in 1 centre.
Discussion
TAVI is an accepted treatment for high-risk patients with
severe symptomatic AS and is the first choice of treatment
for inoperable patients [1, 2]. Nevertheless, TAVI remains
associated with a relatively high number of haemorrhagic
and embolic complications [3, 4]. Moreover, little is known
about antithrombotic treatment strategies and current guide-
lines report only recommendations [5–7] In this survey, we
interviewed centres performing TAVI in the Netherlands re-
garding antithrombotic treatment after TAVI. Althoughmostly
according to one or more recommendations, inter-centre var-
iability of the antithrombotic policy is high.
Haemorrhagic complications are frequent, and major and
disabling or life-threatening bleeding after TAVI occurs in
approximately 22 % and 16 %, respectively [3]. Regardless of
the mechanism, a disabling or life-threatening bleeding is an
important predictor of acute and late mortality [9–13]. More
insight into the role of the antithrombotic treatment regimen
could provide the most desirable antithrombotic treatment to
possibly reduce the rate of disabling or life-threatening bleeding
and adverse outcomes [6].
The most prevalent thromboembolic complication is stroke,
which occurs in approximately 2.5 % to 4.1 % at 30 days [4,
14–16]. Most acute strokes are procedure related and of em-
bolic origin, caused by manipulation with large catheters [17].
The incidence of late stroke is approximately 2% and similar to
that observed to other populations of elderly people [11, 18].
Late strokes are more prevalent in patients with classical risk
factors such as (new-onset) AF [17, 19]. However, in the
PARTNER IB trial, the portion of haemorrhagic stroke after
30 days was higher in the TAVI group than in the medical
treatment group [18], emphasising the double-edged sword of
antithrombotic treatment in the elderly.
Only the American College of Cardiology Foundation/
Society of Thoracic Surgeons (ACCF/AATS/SCAI/STS) Expert
Consensus Document on TAVI has mentioned antithrombotic
treatment during procedure and recommends UFHwith an ACT
>300 s [6]. In the PARTNER I trial, UFH was given in an initial
bolus of 5000 IU with a target ACT >250 s [1, 2]. In this survey,
we found UFH was used in all centres and ACT is routinely
measured in 13 of the 14 interviewed centres. The target ACT
is >300 in only 3 centres and >250 s in 9 of the 14 centres.
Following TAVI, DAPT consisting of aspirin (lifelong) and
clopidogrel (initial period) is currently recommended [5–7].
However, this is largely based on retrospective registries and 2
cases of severe postprocedural thrombocytopenia in patients
treated with clopidogrel without a loading dose in a preliminary
first-in-man studywith the CoreValveTM [20]. A second rationale
for adding clopidogrel to aspirin is supported by the histopatho-
logical finding that incorporation of the CoreValveTM prosthesis
into the aortic wall by means of endothelialisation is a chrono-
logical integration over a period of approximately 3 months [21].
Whereas aspirin (lifelong) is recommended unanimously,
recommendations for the duration of clopidogrel vary from 1 to
3 months [7], 1 to 6 months [5] and 3 to 6 months [6]. In this
survey, we found aspirin was prescribed in all centres according
to recommendations. However, concomitant clopidogrel was
prescribed in 13 of the 14 centres. Duration of concomitant
clopidogrel therapy was 3 months in over two-thirds of cases.
In 2 centres, duration of concomitant clopidogrel was based upon
type of prosthesis: 6 months for CoreValveTM versus 3 months
for intra-annular prostheses (e.g. SAPIENTM, JenaValveTM).
These centres tended to be more careful with CoreValveTM
because of the supra-annular design and longer struts, and pos-
sible subsequent proneness to more thromboembolic complica-
tions, although this has not been described in the literature [4].
In patients with AF or another indication for OAC, the best
antithrombotic treatment regimen is unknown. In these pa-
tients, a combination of OAC and aspirin or thienopyridine is
generally used [5]. We found that in patients with an indica-
tion for OAC, 13 of the 14 centres prescribed concomitant
antiplatelet therapy. Of these, 9 centres used clopidogrel and 4
centres used aspirin.
Concomitant antiplatelet drugs have shown to increase the
risk for major bleeding in patients with AF [22–24]. A recent
Danish registry study shows that in patients with AF and
myocardial infarction, the combination of OAC+clopidogrel
was comparable with triple therapy [25]. However, in the
recent WOEST trial, OAC+clopidogrel was superior to triple
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therapy in patients with AF undergoing drug-eluting stent
placement including a striking decrease in all-cause mortality
[26]. In this survey, 1 centre would continue triple therapy
when a patient received triple therapy prior to TAVI. When
discontinued, 4 centres omitted aspirin in any case and 1
centre omitted clopidogrel in any case. Two centres omitted
aspirin only when patients received triple therapy because of a
recent stent and omitted clopidogrel in other cases. One centre
omitted OAC until clopidogrel could be stopped.
Leaning on a small basis of evidence and recommendations,
we found considerable heterogeneity in the antithrombotic
treatment practised between TAVI performing centres in the
Netherlands. In most TAVI registries, information about anti-
thrombotic treatment is not available. Generalising national
antithrombotic policy may homogenise this factor, making
clinically important outcomes more comparable in addition to
the initiative of VARC-2 [27]. Furthermore, further research is
needed to study the effect of antithrombotic therapy on clinical
outcomes.We are currently setting up amulticentre randomised
controlled clinical trial in the Netherlands, investigating the
safety and efficacy of omitting clopidogrel in the first 3 months
after TAVI versus aspirin+clopidogrel in patients without an
indication for OAC at baseline, and versus OAC+clopidogrel in
patients with an indication for OAC at baseline.
Study limitations
This study presents a description of current clinical practice in
Dutch hospitals with respect to antithrombotic therapy in
patients undergoing TAVI. It does not describe the outcome
and complications of these treatment methods and none of the
interviews were verified with patient data. Furthermore, this
study only describes the current antithrombotic strategy and
does not consider possible previous antithrombotic strategies
or the experience of centres with the TAVI procedure. Finally,
we approached only one cardiologist per centre assuming that
cardiologists belonging to a single hospital and organisation
apply the same strategies.
Conclusion
Leaning on a small basis of evidence and recommendations,
the antithrombotic policy for patients undergoing TAVI is
highly variable in the Netherlands. As a standardised regimen
might further reduce haemorrhagic complications, large
randomised clinical trials may help to establish the most
appropriate approach.
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